Meningitis B Vaccine

Mark Durkan Excerpts

Monday 25th April 2016 Westminster Hall

[Mark Durkan (Foyle) (SDLP)]

It is a pleasure to serve under your chairmanship, Mr Pritchard, and to follow the hon. Member for Faversham and Mid Kent (Helen Whately). She spoke so strongly on behalf of the Burdett family, whom she represents, and about the tragedy they have faced, and she also spoke to the wider issues raised by the petition following Faye’s death.

I thank the hon. Member for Bath (Ben Howlett) for introducing the debate in the way he did, and I also thank the members of the Petitions Committee for the great service they provided to not only the House but the public by holding hearings in conjunction with the Health Committee. These petitions are a new way for Parliament to engage with the public on important issues, and I hope we will learn from this debate that there is also a new way for Members to engage with Ministers to deal with questions that are not always as easy to address as we might want them to be.

Over the past few years, ever since Bexsero was first licensed as a vaccine in Europe, I have tabled a number of early-day motions encouraging the Government and the Joint Committee on Vaccination and Immunisation to move more quickly. Like Meningitis Now and the original Meningitis UK “Beat it now” campaign, I wanted to ensure that we did not have to wait another five years, as we had to for the meningitis C vaccine, with all the accompanying loss of life and life-changing damage done to children in the meantime.

[Peter Dowd (Bootle) (Lab)]

I met Harmonie-Rose the other day, and what a beautiful little girl she is. I do not want to make inappropriate or spurious comparisons, but the swine flu vaccine cost £1 billion, which, despite the criticism, was money well spent. Does the hon. Gentleman agree that a vaccine catch-up programme would also be money well spent?

[Mark Durkan]

I believe that it would. I will come to that point shortly.

Many Government and Opposition MPs in the previous Parliament and this one have been aware of the issues and concerns involved. First, there was the issue of whether we would get the men B vaccine on to the immunisation schedule as soon as we should. Thankfully, steps were taken last spring, and it came on stream in the autumn. The decision that was made by the Department of Health here effectively became the predictive text for what happened in my devolved area, and I welcome the fact that the Health Minister in Northern Ireland followed suit. A similar issue has arisen here. If the Department responds to the evidence that the Petitions Committee and the Health Committee took, which was based on the issues that the petition raised, that will make a difference not only to NHS England, but to my devolved area.

Being based in Northern Ireland, I am conscious that the south of Ireland has taken the decision to follow the UK on the men B vaccine. It will take it up later this year, which may have an impact on the supply of the vaccine. That is why we need to ensure that, when we talk to Government Ministers here and the devolved Ministers, we also talk to the authorities in the south of Ireland. Between us, we have a very good instrument—the British-Irish Council—which brings together all the Administrations on these islands. They should collectively discuss these policy issues and challenges, and they should combine their muscle to improve their negotiating power with Glaxo on any price implications or sensitivities in relation to the drug.

We have been asked to address three main questions, and I hope that the Minister will do so. I know that some will sound like technocratic issues, and perhaps talking in those terms will make the Minister feel uncomfortable or insensitive. There are the issues that delayed the men B vaccine being put on the schedule in the first place and the issues that we face now, particularly the cost-effectiveness framework. As many hon. Members have said, the framework needs to be adjusted to take into account peace of mind factors and the lifelong impact on those who survive meningitis but suffer lasting damage and have difficulties with the economic and social costs that arise from that. The hon. Member for Bath addressed the issue of ensuring that there is a commitment to funding the adolescent intervention study. Rightly, he did not over-speculate about that, but we need to fully understand it and see what can come of it.

As the hon. Member for Bootle (Peter Dowd) said, there is the question of the under-fives catch-up. Most parents understand that that is a basic thing that should be done. People find it hard to believe that there is a significant case against it; they think it is just a question of how we manage and organise it. It is not enough to say, “If we reach the newborns, that will be enough.” The risk is significant.

Like the hon. Gentleman, I met Harmonie-Rose last week in Westminster Hall. I could not help but be conscious that I was talking to a beautiful, lovely child, and that perhaps, if the men B vaccine had been on stream earlier and in the immunisation schedule when it was licensed, she would not have had to use her great charm to lobby on this issue.

If we delay the under-fives catch-up, how many other people will be affected? How many other young, precious lives will be lost? How many families will be plunged into grief? How many young lives will be harmed? How many young people will lose limbs or suffer brain damage or facial disfiguration? We need a response and an intervention, which is why people have petitioned so strongly. The people who petitioned us want action, and I hope the Minister will address them in honest but hopeful terms.